Login / Signup

Computational repurposing of benzimidazole anthelmintic drugs as potential colchicine binding site inhibitors.

Muhammad KhattabAhmed Ali Al-Karmalawy
Published in: Future medicinal chemistry (2021)
Background: Although some benzimidazole-based anthelmintic drugs are found to possess anticancer activity, their modes of binding interactions have not been reported. Methodology: In this study, we aimed to investigate the binding interactions and electronic configurations of nine benzimidazole-based anthelmintics against one of the well-known cancer targets (tubulin protein). Results: Binding affinities of docked benzimidazole drugs into colchicine-binding site were calculated where flubendazole > oxfendazole > nocodazole > mebendazole. Flubendazole was found to bind more efficiently with tubulin protein than other drugs. Quantum mechanics studies revealed that the electron density of HOMO of flubendazole and mebendazole together with their molecular electrostatic potential map are closely similar to that of nocodazole. Conclusion: Our study has ramifications for considering repurposing of flubendazole as a promising anticancer candidate.
Keyphrases
  • molecular docking
  • binding protein
  • dna binding
  • squamous cell carcinoma
  • protein protein
  • papillary thyroid
  • young adults
  • risk assessment
  • amino acid
  • human health
  • small molecule
  • childhood cancer
  • electron transfer